Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Starting treatment news


From To
Elvitegravir "Quad" single-tablet regimen shows continued HIV suppression at 48 weeks

Gilead Science's experimental "Quad" pill - a once-daily single-tablet coformulation containing the new integrase inhibitor elvitegravir, the novel boosting agent cobicistat (GS 9350), and tenofovir plus emtricitabine  continued to demonstrate potent antiviral activity and good tolerability at 48 weeks, according to data presented this week at the 50th ICAAC.

15 September 2010
FDA Approves New Labeling For ISENTRESS® To Include 96-Week Efficacy And Tolerability Data In Adult Patients Infected With HIV-1

Merck announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for ISENTRESS® (raltegravir) tablets to include 96-week data, which demonstrates the durable efficacy of ISENTRESS in HIV-1 infected patients. ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults...

06 August 2010
Medical News Today
Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti

Full results of the Haitian study showing that early treatment, after the CD4 cell count falls below 350, reduces the risk of death in low-income settings.

14 July 2010
New England Journal of Medicine
← Prev1...1516171819Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.